BenevolentAI, a drug discovery company, is looking to raise money at a “level far below” the bn valuation bequeathed on it last year by investors including Woodford Investment Management, according to a report from the Sunday Times.News of a potential down round follows FT Alphaville's long analysis of the business, published over a fortnight ago. The company was brought to our attention thanks to its prominence in Woodford's investment vehicles, including the now-gated Equity Income Fund and the Patient Capital Trust.The Sunday Times article covers the story well, but one thing missed is that, as of December, BenevolentAI had yet to draw down the full £84.1m it raised last year. According to Companies House filings, the medical technology business still had £20.5m to come in as of Dec
FT Alphaville considers the following as important:
This could be interesting, too:
Tyler Cowen writes Rhino bond markets in everything
Tyler Cowen writes Thursday assorted links
Menzie Chinn writes The Course of the US-China Trade War, Viewed through the Lens of Soybeans
Shlomo Ben-Ami writes No Economic Peace for Palestinians
BenevolentAI, a drug discovery company, is looking to raise money at a “level far below” the...